Forbion
Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug
Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases
Dutch Biotech Citryll Secures €85M Funding from J&J and Novartis for Inflammatory Disease Therapy
Citryll, Inflammatory disease therapy, Neutrophil Extracellular Traps (NETs), Series B funding, Johnson & Johnson Innovation, Novartis Venture Fund, Forbion
Forbion Secures Over €2 Billion in Largest Fundraising to Date, Supporting 30 Biotechs
Forbion, venture capital, life sciences, fundraising, biotechs, Forbion Growth Opportunities Fund III, Forbion Ventures Fund VII
Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody
Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion